← All trials
NCT00111943
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2005
- Primary completion
- —
- Completion date
- Oct 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Bronx Lebanon Hospital CenterStudy chair
- National Institute on Drug Abuse (NIDA)Collaborator
- National Institute of Mental Health (NIMH)Collaborator
- National Institutes of Health (NIH)Collaborator
- University of Alabama, BirminghamStudy chair
- University of PittsburghStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.